Most Viewed Videos

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy

Bruce D. Cheson, MD, and Richard I. Fisher, MD, on Lymphoma: Treatment Considerations

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery

Heinz-Josef Lenz, MD, on Pancreatic Cancer Tumor Profiling and Treatment Response: Results From the COMPASS Trial

Eric Jonasch, MD, on Kidney Cancer: A Year in Review

Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Silke Gillessen, MD, on Prostate Cancer: Results From the REDUSE Trial on Denosumab

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

May

Today In Oncology

FDA Pipeline: Designations in Myeloma, Adenoid Cystic Carcinoma, and Kaposi Sarcoma, Plus ODAC Votes

Does Quitting Smoking Affect Risk of Bladder Cancer in Postmenopausal Women?

Rate of 'Textbook Outcomes' in Curative-Intent Resection of Intrahepatic Cholangiocarcinoma

Control Arm Quality in Randomized Oncology Trials Leading to FDA Approval

Impact of Establishment of Cancer Urgent Care Clinic on Emergency Department Visits

;

Front-Line Therapy in Advanced Renal Cell Carcinoma: Developing a New Standard

Harnessing the Power of Twitter for Clinical Trial Enrollment and Success

2019 ASCO: Reduced Chemotherapy Dosages in Elderly Patients With Advanced Gastroesophageal Cancer

Management of HER2-Positive Breast Cancer: Business as Usual?

2019 ASCO: Entrectinib in Children and Adolescents With Recurrent or Refractory Solid or Central Nervous System Tumors

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Pieter Tanis, MD, PhD, on Colon Cancer: Results From the COLOPEC Trial on Adjuvant HIPEC

John G. Gribben, MD, DSc, on The Tumor Microenvironment, Prognosis, and Outcome

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

Pieter Tanis, MD, PhD, on Colon Cancer: Results From the COLOPEC Trial on Adjuvant HIPEC

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Sagar Lonial, MD, on Multiple Myeloma: Sequencing Therapies

Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents

John G. Gribben, MD, DSc, on The Tumor Microenvironment, Prognosis, and Outcome

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy

Bruce D. Cheson, MD, and Richard I. Fisher, MD, on Lymphoma: Treatment Considerations

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery

Heinz-Josef Lenz, MD, on Pancreatic Cancer Tumor Profiling and Treatment Response: Results From the COMPASS Trial

Eric Jonasch, MD, on Kidney Cancer: A Year in Review

Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Silke Gillessen, MD, on Prostate Cancer: Results From the REDUSE Trial on Denosumab

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

FDA Pipeline: Designations in Myeloma, Adenoid Cystic Carcinoma, and Kaposi Sarcoma, Plus ODAC Votes

Does Quitting Smoking Affect Risk of Bladder Cancer in Postmenopausal Women?

Rate of 'Textbook Outcomes' in Curative-Intent Resection of Intrahepatic Cholangiocarcinoma

Control Arm Quality in Randomized Oncology Trials Leading to FDA Approval

Impact of Establishment of Cancer Urgent Care Clinic on Emergency Department Visits

Front-Line Therapy in Advanced Renal Cell Carcinoma: Developing a New Standard

Harnessing the Power of Twitter for Clinical Trial Enrollment and Success

2019 ASCO: Reduced Chemotherapy Dosages in Elderly Patients With Advanced Gastroesophageal Cancer

Management of HER2-Positive Breast Cancer: Business as Usual?

2019 ASCO: Entrectinib in Children and Adolescents With Recurrent or Refractory Solid or Central Nervous System Tumors

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Pieter Tanis, MD, PhD, on Colon Cancer: Results From the COLOPEC Trial on Adjuvant HIPEC

John G. Gribben, MD, DSc, on The Tumor Microenvironment, Prognosis, and Outcome

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing